Tag: GlobeNewswire

LUGANO, Switzerland and BERTRANGE, Luxembourg, Oct. 01, 2026 (GLOBE NEWSWIRE) — Trasteel Holding S.A. (“Trasteel” or the “Company”), a global steel trading and industrial group headquartered in Lugano (Switzerland) and Luxembourg, and Sizzle Acquisition Corp. II (Nasdaq: SZZL) (“Sizzle II”), a publicly traded special purpose acquisition company, today announced that Trasteel S.A. (“Pubco”), a newly formed Luxembourg holding company, confidentially submitted a draft registration statement on Form F-4 (as amended from time to time, the “Registration Statement”) to the U.S. Securities and Exchange Commission (the “SEC”) on September 30, 2026. The Registration Statement relates to the previously announced business combination agreement, dated as of April 13, 2026, as amended (the “Business Combination Agreement”), by and among Sizzle II, Trasteel, Pubco and the parties thereto. 

The submission of the Registration Statement marks an important milestone toward the completion of the previously disclosed proposed business combination between Trasteel and Sizzle II, announced on April 13, 2026 (press release). The Registration Statement has not been filed, or declared effective, and remains subject to review, by the SEC.

Under the Business Combination Agreement, Pubco will, upon closing of its business combination, acquire all of the issued and outstanding shares of Trasteel in exchange for Pubco ordinary shares, and Trasteel Merger Sub Limited, a wholly owned subsidiary of Pubco, will merge with and into Sizzle II, with each of Trasteel and Sizzle II surviving as a wholly owned subsidiary of Pubco.

The business combination is subject to the Registration Statement being filed with and declared effective by the SEC, and the approval of the business combination by Sizzle II’s shareholders, among other conditions set forth in the Business Combination Agreement. Upon its closing, Pubco is expected to be listed on the Nasdaq Stock Market under the ticker symbol “TSTL”.

About Trasteel

Trasteel is a global steel trading and industrial group founded in 2009, operating across more than 60 countries with over 1,400 employees. The Company combines trading operations with industrial transformation activities and serves over 4,000 customers worldwide.

For more information, please visit www.trasteel.com

About Sizzle Acquisition Corp. II

Sizzle II is a blank check company, incorporated as a Cayman Islands exempted company, formed for the purpose of entering into a merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization, or other similar business combination with one or more businesses or entities. Sizzle II is led by Chairman and CEO Steve Salis and Vice Chairman Jamie Karson, and its management team includes Daniel Lee, its CFO. Its board of directors comprises Steve Salis, Jamie Karson, Neil Leibman, David Perlin and Warren Thompson. Its board of advisors comprises Rick Camac, Michael Kuchta, Ryan Croft, Craig Curley and Tony Sage.

For more information, please visit https://sizzlespac.com

About Pubco

Trasteel S.A. (“Pubco”) is a newly formed Luxembourg public limited liability company (société anonyme) that will serve as the publicly traded holding company for the combined business following the closing of the proposed business combination.

Additional Information and Where to Find It

This press release is provided for informational purposes only and relates to the proposed business combination (the “Proposed Business Combination”) pursuant to the Business Combination Agreement, by and among Sizzle II, Trasteel, Pubco and the parties thereto. Subject to its terms and conditions, the Business Combination Agreement provides that at closing each of Sizzle II and Trasteel will become wholly owned subsidiaries of Pubco.

In connection with the Proposed Business Combination, Pubco has confidentially submitted, the Registration Statement with the SEC, which includes a proxy statement of Sizzle II and a prospectus for the registration of Pubco securities (as amended from time to time, the “proxy statement/prospectus”). The Registration Statement has not been filed with the SEC and has not been declared effective by the SEC.  Upon the occurrence of the Registration Statement being declared effective, its definitive proxy statement/prospectus and other relevant documents will be mailed to Sizzle II shareholders as of the record date to be established for purposes of voting on the Proposed Business Combination. INVESTORS AND SHAREHOLDERS OF SIZZLE II AND OTHER INTERESTED PERSONS ARE URGED TO READ, WHEN AVAILABLE, THE PRELIMINARY PROXY STATEMENT/PROSPECTUS, ANY AMENDMENTS THERETO, THE DEFINITIVE PROXY STATEMENT/PROSPECTUS AND ALL OTHER RELEVANT DOCUMENTS FILED OR TO BE FILED WITH THE SEC IN CONNECTION WITH THE PROPOSED BUSINESS COMBINATION, BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT SIZZLE II, TRASTEEL, PUBCO AND THE PROPOSED BUSINESS COMBINATION.

Shareholders and other interested persons will be able to obtain copies of the preliminary proxy statement/prospectus, the definitive proxy statement/prospectus and other relevant materials, without charge, once available, at the SEC’s website at www.sec.gov, or by directing a request to: Sizzle Acquisition Corp. II, 4201 Georgia Avenue, NW, Washington, D.C. 20011, Attn: Steve Salis, Chief Executive Officer. The information contained on, or that may be accessed through, the websites referenced in this press release is not incorporated by reference into, and is not a part of, this press release.

Participants in the Solicitation

This press release is not a solicitation of a proxy from any investor or securityholder. Sizzle II, Trasteel, Pubco and their respective directors and executive officers may be deemed under SEC rules to be participants in the solicitation of proxies from Sizzle II’s shareholders in connection with the Proposed Business Combination. Sizzle II’s shareholders and other interested persons may obtain, without charge, more detailed information regarding the directors and officers of Sizzle II in Sizzle II’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025, filed with the SEC on March 12, 2026 (the “Sizzle II Form 10-K”). Information regarding the persons who may, under SEC rules, be deemed participants in the solicitation of proxies to Sizzle II’s shareholders, and a description of their interests in the Proposed Business Combination, will be set forth in the proxy statement/prospectus when it is filed with the SEC. You may obtain copies of these documents, once available, at the SEC’s website at www.sec.gov or by directing a request to the address provided above.

No Offer or Solicitation

This press release is not a proxy statement or solicitation of a proxy, consent or authorization with respect to any securities or in respect of the Proposed Business Combination and shall not constitute an offer to sell or a solicitation of an offer to buy any securities, or a solicitation of any vote or approval, nor shall there be any sale of securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. No offer of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended (the “Securities Act”), or an exemption therefrom.

The securities to be issued by Pubco in connection with the Proposed Business Combination have not been registered under the Securities Act, and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the Securities Act.

NEITHER THE SEC NOR ANY STATE SECURITIES REGULATORY AGENCY HAS APPROVED OR DISAPPROVED THE PROPOSED BUSINESS COMBINATION DESCRIBED HEREIN, PASSED UPON THE MERITS OR FAIRNESS OF THE PROPOSED BUSINESS COMBINATION OR ANY RELATED TRANSACTIONS, OR PASSED UPON THE ADEQUACY OR ACCURACY OF THE DISCLOSURE IN THIS PRESS RELEASE. ANY REPRESENTATION TO THE CONTRARY CONSTITUTES A CRIMINAL OFFENSE.

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Sizzle II’s, Trasteel’s and/or Pubco’s actual results may differ from their expectations, estimates and projections and, consequently, you should not rely on these forward-looking statements as predictions of future events. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions, and other statements that are other than statements of historical fact. No representations or warranties, express or implied, are given in, or in respect of, this press release. When words such as “may,” “will,” “intend,” “should,” “believe,” “expect,” “anticipate,” “project,” “estimate” or similar expressions that do not relate solely to historical matters are used, such terms are, among others, used in the context of making forward-looking statements.

These forward-looking statements, and factors that may cause actual results to differ materially from current expectations, include, but are not limited to, the following, which reflect the risk factors described in the Registration Statement:

Risks relating to Trasteel’s business and industry: the tie of Trasteel’s results to cyclical global steel and raw-material prices; the risk that Trasteel’s back-to-back, hedged trading model may not fully offset price risk; global steel oversupply, China’s dominant share of production and shifting trade flows; intense competition and disintermediation; the dependence of Trasteel’s growth strategy on acquiring and integrating industrial assets; geographic concentration of revenues in the European Union, particularly Italy; and tariffs, trade remedies, sanctions and the EU Carbon Border Adjustment Mechanism; dependence on trade-finance and credit facilities;

Risks relating to Pubco’s structure and jurisdiction: Pubco’s status as a Luxembourg company and as a “foreign private issuer,” including its exemption from certain U.S. securities rules and the possible loss of foreign private issuer status; the governance of shareholder rights under Luxembourg law and the differences between Luxembourg and European insolvency laws and those of the United States; the potential difficulty of enforcing judgments against Pubco or its directors, whose assets are located outside the United States; the concentration of ownership of Pubco Ordinary Shares among Trasteel’s principal shareholders following the Business Combination; and identified material weaknesses in internal control over financial reporting and substantial doubt about the ability to continue as a going concern;

Risks relating to the Proposed Business Combination and Sizzle II: the ability of the parties to complete the Proposed Business Combination in a timely manner or at all; the risk that Sizzle II does not consummate the Business Combination by April 3, 2027 and is required to liquidate and dissolve; the failure to obtain the approval of Sizzle II’s shareholders or to satisfy the minimum cash condition or other closing conditions; the level of redemptions by Sizzle II’s public shareholders and the resulting reduction in available cash and working capital and effect on Sizzle II’s strategic plan; conflicts of interest of the Sponsor and Sizzle II’s directors and officers; the ability to obtain and maintain the listing of Pubco Ordinary Shares on Nasdaq; the risks of becoming a public company through a special purpose acquisition company rather than an underwritten offering, including the absence of an underwriter’s independent due diligence review; the costs of the Proposed Business Combination and of operating as a public company; the effect of the announcement or pendency of the Proposed Business Combination on Trasteel’s and Sizzle II’s business relationships, operating results and operations; the absence of a prior public market for, and the potential illiquidity of, Pubco Ordinary Shares, and the effect of future sales of shares; and the intention not to pay dividends; and those factors discussed under the heading “Risk Factors” in the Registration Statement and in the Sizzle II Form 10-K, and other documents Sizzle II has filed, or that Sizzle II or Pubco will file, with the SEC.

The foregoing list of factors is not exhaustive. You should carefully consider the foregoing factors and the other risks and uncertainties described in the “Risk Factors” section of the Registration Statement referenced above, the final prospectus of Sizzle II dated March 31, 2025 and filed with the SEC on April 2, 2025, Sizzle II’s most recent Quarterly Report on Form 10-Q filed with the SEC on August 12, 2026, the Sizzle II Form 10-K, and other documents filed or to be filed by Sizzle II and Pubco from time to time with the SEC. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. There may be additional risks that none of Sizzle II, Trasteel or Pubco presently know, or that they currently believe are immaterial, which in each case could cause actual results to differ from those contained in the forward-looking statements. For these reasons, among others, investors and other interested persons are cautioned not to place undue reliance upon any forward-looking statements in this press release. None of Sizzle II, Trasteel or Pubco undertakes any obligation to publicly revise any forward-looking statements to reflect events or circumstances that arise after the date of this press release, except as required by applicable law.

Media Contacts

Trasteel Holding S.A.

Investor Relations
Alessandro Colombi – Head of IR
e-mail: ir@trasteel.com

Media Relations
Alessandro Colombi – Head of IR
e-mail: press@trasteel.com

Investor Relations Advisor

Alpha IR Group
Michael Cummings – President
e-mail: tstl@alpha-ir.com

Media Relations Advisor

Alpha IR Group
James McCusker – Senior Managing Director
e-mail: tstl@alpha-ir.com

AUSTIN, Texas, Oct. 01, 2026 (GLOBE NEWSWIRE) — Digital Realty (NYSE: DLR), the world’s largest cloud- and carrier-neutral data center platform, today announced that it will release financial results for the third quarter of 2026 after the market closes on Thursday, October 29, 2026. The company will host a conference call to discuss these results at 5:00 p.m. ET / 4:00 p.m. CT on Thursday, October 29, 2026. 

A live webcast of the call will be available on the Investors section of Digital Realty’s website at https://investor.digitalrealty.com. The webcast will be archived until October 29, 2027 and the replay will be available shortly after the conclusion of the live event.

About Digital Realty

Digital Realty brings companies and data together by delivering the full spectrum of data center, colocation, and interconnection solutions. PlatformDIGITAL®, the company’s global data center platform, provides customers with a secure data meeting place and a proven Pervasive Datacenter Architecture (PDx®) solution methodology for powering innovation, from cloud and digital transformation to emerging technologies like artificial intelligence (AI), and efficiently managing Data Gravity challenges. Digital Realty gives its customers access to the connected data communities that matter to them with a global data center footprint of 300+ facilities in 55+ metros across 30+ countries on six continents. To learn more about Digital Realty, please visit digitalrealty.com or follow us on LinkedIn and X.

For Additional Information

Investor Relations
Jordan Sadler / Jim Huseby
Digital Realty
+1 (737) 281-0101
InvestorRelations@digitalrealty.com

SAN DIEGO, Oct. 01, 2026 (GLOBE NEWSWIRE) — Resmed (NYSE: RMD, ASX: RMD) today announced it plans to release financial and operational results for the first quarter of fiscal year 2027 on Thursday, October 29, 2026, after the New York Stock Exchange closes. Following the release, Resmed management will host a webcast to discuss the results. Other forward-looking and material information may also be discussed during the webcast.

Earnings webcast details:

• Location:            https://investor.resmed.com
• Date:                  Thursday, October 29, 2026
• Time:                  1:30 p.m. PT / 4:30 p.m. ET
• International:      London, Thursday, October 29, 2026, 8:30 p.m. GMT

                                   Sydney, Friday, October 30, 2026, 7:30 a.m. AEDT

Please note, Resmed does not use outside phone lines to access the earnings call, the call is accessible via the above webcast link only.

A replay of the earnings webcast will be accessible on Resmed’s investor relations website and available approximately two hours after the webcast. In addition, a phone replay will be available approximately three hours after the webcast and will be accessible from October 29, 2026, until November 12, 2026, at:

• U.S.: +1 877.660.6853
• International: +1 201.612.7415
• Conference ID: 13762822

About Resmed
Resmed (NYSE: RMD, ASX: RMD) creates life-changing health technologies that people love. We’re relentlessly committed to pioneering innovative technology to empower millions of people in 140 countries to live happier, healthier lives. Our AI-powered digital health solutions, cloud-connected devices and intelligent software make home healthcare more personalized, accessible and effective. Ultimately, Resmed envisions a world where every person can achieve their full potential through better sleep and breathing, with care delivered in their own home. Learn more about how we’re redefining sleep health at Resmed.com and follow @Resmed.

For investors		For media
+1 858.221.3304		+1 619.510.1281
investorrelations@Resmed.com		news@Resmed.com

         
                            

Zug, Switzerland, October 1, 2026 – WISeQey Corp. (formerly known as WISeKey International Corp., “WISeQey” or the “Company”) (SIX: WIHN; NASDAQ: WKEY), a leading global quantum cybersecurity and space IoT company, today announced that the previously announced redomiciliation of WISeKey International Holding Ltd (“WISeKey”) from Switzerland to the British Virgin Islands became legally effective today (the “Redomiciliation”). The Redomiciliation was implemented through a cross-border merger of WISeKey with and into WISeQey, its wholly owned British Virgin Islands subsidiary, with WISeQey as the surviving company (the “Merger”).

The existing American Depositary Shares of WISeKey will continue to trade on Nasdaq, and the existing Class B shares of WISeKey will continue to trade on the SIX Swiss Exchange, in each case through the close of business on Friday, October 2, 2026. The ordinary shares of WISeQey are expected to commence trading under the ticker symbol “WQEY” on both the Nasdaq Global Market and the SIX Swiss Exchange (where they will have a primary listing) at market open on Monday, October 5, 2026.

Following cancellation of the existing WISeKey equity securities, holders of WISeKey equity securities will receive the applicable equity securities of WISeQey in accordance with the exchange ratios, elections, and settlement procedures previously communicated to shareholders and described in the prospectus relating to the Merger.

In connection with the completion of the Redomiciliation, (i) each WISeKey ADS will be exchanged for one-half of one WISeQey ordinary share, (ii) each WISeKey Class B share will be exchanged for one WISeQey ordinary share (unless such holder elected to receive WISeQey Class B shares), and (iii) each WISeKey Class B share held by a holder that elected to receive unlisted WISeQey Class B shares will be exchanged for ten WISeQey Class B shares.

About WISeQey

WISeQey Corp. (“WISeQey”), is a British Virgin Islands holding company focused on post quantum cybersecurity, digital identity, space technology and the Internet of Things (IoT). Its operating subsidiaries and technology platforms address distinct parts of this portfolio:

1. SEALSQ Corp (Nasdaq: LAES) develops secure semiconductors, public key infrastructure (PKI) and post-quantum security products.
2. WISeSat AG develops space technology and secure satellite communications, particularly for IoT applications.
3. WISeID provides digital identity, authentication, secure access and digital signing for individuals, enterprises and connected devices.
4. WISe.ART Corp operates the WISe.ART marketplace, which uses blockchain technology to support trusted digital asset and NFT transactions.
5. SEALCOIN AG develops decentralized physical infrastructure network (DePIN) technology and the SEALCOIN platform.

Each subsidiary contributes to WISeQey’s mission of securing the internet while focusing on their respective areas of research and expertise. Their technologies seamlessly integrate into the comprehensive WISeQey platform. WISeQey secures digital identity ecosystems for individuals and objects using blockchain, AI, and IoT technologies. With over 1.6 billion microchips deployed across various IoT sectors, WISeQey plays a vital role in securing the Internet of Everything. Trusted by the OISTE/WISeKey cryptographic Root of Trust, WISeQey provides secure authentication and identification for IoT, blockchain, and AI applications. The WISeQey Root of Trust ensures the integrity of online transactions between objects and people. For more information on WISeQey’s strategic direction and its subsidiary companies, please visit www.wisekey.com.

Forward-Looking Statements

This communication contains forward-looking statements concerning WISeKey International Holding Ltd, WISeQey Corp. and/or their respective subsidiaries (collectively, “WISeKey,” “WISeQey,” “our” or “us”) and their businesses. Forward-looking statements can be identified by terms such as “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “project,” “will,” and similar expressions. These statements involve known and unknown risks, uncertainties and other factors that could cause WISeKey’s or WISeQey’s actual results, financial condition, performance or achievements to differ materially from any future results, performance or achievements expressed or implied by such forward-looking statements. These factors include: the expected timing of the commencement of trading of WISeQey ordinary shares on the Nasdaq Global Market and the SIX Swiss Exchange; the completion of the exchange of WISeKey equity securities for WISeQey equity securities; the ability of WISeQey to realize the anticipated benefits of the Redomiciliation; and the risks discussed in WISeKey’s and WISeQey’s filings with the SEC. WISeKey and WISeQey are providing this communication as of this date and do not undertake to update any forward-looking statements as a result of new information, future events or otherwise.

This press release does not constitute an offer to sell, or a solicitation of an offer to buy, any securities, and it does not constitute an offering prospectus within the meaning of the Swiss Financial Services Act (“FinSA”), the FinSA’s predecessor legislation or advertising within the meaning of the FinSA. Investors must rely on their own evaluation of WISeKey and its securities, including the merits and risks involved. Nothing contained herein is, or shall be relied on as, a promise or representation as to the future performance of WISeKey. Given the risks and uncertainties described herein, you should not place undue reliance on forward-looking statements as a prediction of actual results.

Press and Investor Contacts

WISeQey Corp. Company Contact: Carlos Moreira Chairman & CEO Tel: +41 22 594 3000 info@wisekey.com

WISeQey Investor Relations (US)  The Equity Group Inc. Lena Cati Tel: +1 212 836-9611 lena.cati@theequitygroup.com

Acquisition Expands Global Footprint in Collectibles, Fine Art, and Antiques with Additional Scale, Services and Innovation for Auction Houses and Bidders

BETHESDA, Md., Oct. 01, 2026 (GLOBE NEWSWIRE) — Liquidity Services (NASDAQ:LQDT; www.liquidityservices.com), a leading global provider of e-commerce marketplace solutions that power the circular economy, today announced that it has completed the acquisition of Auction Holdings, Inc., which operates Invaluable, AuctionZip, and RFC Auction Systems, leading online marketplace and technology platforms serving auction houses, collectors and buyers in the collectibles, fine art, antiques, jewelry, decorative arts, and estate markets.

An industry pioneer, Invaluable operates a trusted, leading global online auction marketplace and suite of technology solutions that power the management and sale of treasured, one-of-a-kind items for thousands of auction houses and millions of collectors. Invaluable’s large global buyer base, private-label and auction-management software, integrated marketing services, payments and shipping capabilities allow sellers to maximize sales and operational efficiencies in the $10 Billion+ collectibles, art and antiques market as it continues its transition to online commerce. Additionally, AuctionZip operates a U.S.-focused online auction marketplace and directory that connects local and regional auctioneers with millions of buyers across estate, collectibles, furniture, jewelry, decorative art, real estate and other categories in the lower middle market.

For its four million buyers and collectors, Invaluable provides a convenient online marketplace to research, bid, and buy items from auction houses worldwide on its multi-currency, multi-lingual platform. The platform’s proprietary pricing data developed over two decades is offered via a subscription service to help sellers and buyers enhance their underwriting and analysis of the global collectibles, fine art and antiques marketplace.

The acquisition supports Liquidity Services’ strategy to invest in marketplace platforms in sectors ripe for innovation and Invaluable’s business is highly complementary to Liquidity Services’ core capabilities and markets. Liquidity Services expects to leverage its marketplace operating expertise, buyer monetization capabilities, technology and security infrastructure and value-added services experience to help auction houses increase sales, improve transaction execution and pursue growth across the combined platform.

“We are excited to welcome the talented team and customers of Invaluable to the Liquidity Services family,” said Bill Angrick, Chairman and CEO of Liquidity Services. “Our shared goal is to help Invaluable’s auction-house customers innovate and grow their business by strengthening the technology, services and buyer-engagement tools available to them. By combining Invaluable’s category leadership with Liquidity Services’ proven marketplace operating and merchandising capabilities, we will create meaningful value for auction houses, buyers and shareholders.”

“Invaluable has spent decades building a trusted technology platform for auction houses and collectors around the world,” said Brett Malone, CEO of Invaluable. “Joining Liquidity Services will allow us to accelerate our product roadmap in areas such as shipping and payments, lean into AI to unlock new efficiencies and experiences, expand global demand, and deliver the best possible platform for both bidders and auction houses. We expect these efforts will help auction houses increase bidder participation, improve sell-through and grow their businesses. We look forward to continuing to serve auction-house customers under the Invaluable and AuctionZip brands, with the same customer-first approach and category expertise they know today, while gaining access to additional resources and marketplace expertise from Liquidity Services.”

Following the closing, Invaluable’s leadership team is expected to remain with and continue to operate the Invaluable and AuctionZip businesses that serve thousands of auction houses and provide access to approximately four million registered bidders globally, processing more than $500 million of gross merchandise sales through their platform for their most recent fiscal year ended December 31, 2025.

Liquidity Services acquired the businesses for a base purchase price of $80 million in cash, on a debt-free, cash-free basis, subject to customary adjustments, funded with cash on hand. The acquisition is expected to be accretive to the company’s GAAP and Non-GAAP Adjusted Diluted EPS in FY27.

Canaccord Genuity acted as exclusive financial advisor to Invaluable.

About Invaluable
Invaluable is the world’s leading online marketplace and technology platform for estate, fine art, antiques and collectibles auctions.  Invaluable enables more than four million collectors around the globe to discover and acquire objects they are passionate about, with confidence and convenience, from thousands of the world’s premier traditional auction houses. Invaluable software and services help auction houses manage and market auctions online. For more than twenty years, its innovations have powered the technology, marketing and research needs of some of the most successful brands in the global auction industry, including Sotheby’s, Bonhams, Artcurial and Tajan, to name a few of the thousands of auction houses served.

About Liquidity Services
Liquidity Services (NASDAQ:LQDT) is the leading global provider of e-commerce marketplaces and software solutions powering the circular economy with over $15 billion in completed transactions to more than six million qualified buyers and 15,000 corporate and government sellers worldwide. The company supports its clients’ sustainability efforts by helping them extend the life of assets, prevent unnecessary waste and carbon emissions, and reduce the number of products headed to landfills.

Note on Non-GAAP Measures
Liquidity Services has not provided a reconciliation of its expected fiscal 2027 accretion to Non-GAAP Adjusted Diluted EPS to the most directly comparable GAAP measure because the timing and amount of certain reconciling items, including acquisition-related expenses, amortization of acquired intangible assets and related tax effects, cannot be reasonably estimated without unreasonable effort. These items could materially affect GAAP results and the acquisition’s impact on GAAP diluted earnings per share.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding expected accretion to Non-GAAP Adjusted Diluted EPS in fiscal year 2027, anticipated synergies and other benefits of the acquisition, growth opportunities, expansion and adoption of value-added services, technology and product development plans, integration plans and expected leadership continuity. These statements are based on current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially, including failure or delay in achieving anticipated accretion, synergies and other benefits; higher-than-expected integration costs, business disruption and diversion of management resources; loss of auction-house customers, buyers, key employees or other business relationships; slower adoption of online auctions and paid services, reduced auction supply, bidder demand or asset values, and competitive pricing pressure; difficulties executing technology and product development plans, modernizing systems and migrating data; disruptions or changes affecting third-party search, marketing, cloud, payment and shipping services, including AI-driven changes in traffic and customer acquisition; cybersecurity incidents, data privacy and security obligations, transaction fraud, payment disputes and reputational harm; liabilities arising from pre-closing operations; tax and regulatory requirements; acquisition-related accounting adjustments and goodwill or intangible-asset impairment; and changes in economic and market conditions, including geopolitical conflicts such as the U.S.–Israel–Iran conflict and resulting effects on energy prices, inflation, transportation, sanctions, trade and currency exchange rates. Additional risks are described in Part I, Item 1A of Liquidity Services’ Annual Report on Form 10-K for the fiscal year ended September 30, 2025, Part II, Item 1A of its Quarterly Report on Form 10-Q for the quarter ended June 30, 2026, and subsequent filings with the Securities and Exchange Commission. Forward-looking statements speak only as of the date of this press release. Liquidity Services undertakes no obligation to update any forward-looking statements except as required by law.

CONTACT: Contact:
Investor Relations
investorrelations@liquidityservices.com

MONTREAL, Oct. 01, 2026 (GLOBE NEWSWIRE) — TFI International Inc. (NYSE and TSX: TFII), a North American leader in the transportation and logistics industry, today announced that it will release its financial results for the third quarter ended September 30, 2026, via news release on Thursday, October 29, 2026, after market close. The company will host a webcast with Alain Bédard, Chairman, President and Chief Executive Officer, and David Saperstein, Chief Financial Officer, on Thursday, October 29, 2026, at 5:00 PM Eastern Time, to discuss results.

Webcast Details:

• Date: Thursday, October 29, 2026
• Time: 5:00 PM Eastern Time
• Live webcast & replay: Presentations & Reports within the Investors section of the Company website. Alternatively for the live webcast visit webcast.

ABOUT TFI INTERNATIONAL

TFI International Inc. is a North American leader in the transportation and logistics industry, operating across the United States, Canada and Mexico through its subsidiaries. TFI International creates value for shareholders by identifying strategic acquisitions and managing a growing network of wholly-owned operating subsidiaries. Under the TFI International umbrella, companies benefit from financial and operational resources to build their businesses and increase their efficiency. TFI International companies service the following segments:

• Less-Than-Truckload;
• Truckload;
• Logistics.

TFI International Inc. is publicly traded on the New York Stock Exchange and the Toronto Stock Exchange under the symbol TFII. For more information, visit www.tfiintl.com.

For further information:
Alain Bédard
Chairman, President and CEO
TFI International Inc.
647-729-4079
abedard@tfiintl.com

RADNOR, Pa., Oct. 01, 2026 (GLOBE NEWSWIRE) — Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and aldosterone-related adverse outcomes in comorbid conditions such as chronic kidney disease, obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone, today announced that five abstracts will be presented at the American Heart Association (AHA) Hypertension Scientific Sessions 2026, taking place October 7-11 in Arlington, VA.

Oral Presentation Details:

Title:	Efficacy and Safety of the Selective Aldosterone Synthase Inhibitor Lorundrostat in Moderate-to-Severe Obstructive Sleep Apnea and Hypertension: Explore-OSA Randomized Crossover Trial
Presenter:	Reena Mehra, MD, MS, Professor of Medicine and Division Head, Pulmonary, Critical Care and Sleep Medicine, University of Washington
Session Time:	Thursday, October 8, 11:45 am ET
Session Title:	Clinical Trials and Care Delivery Innovation in Hypertension
Session Location:	Potomac Room

Poster Presentation Details:

Title:	Blood Pressure Responder Analysis in the Global Launch-HTN Trial of Lorundrostat in Uncontrolled and Resistant Hypertension
Presenter:	Manish Saxena, MBBS, Deputy Clinical Co-Director of Queen Mary University of London’s William Harvey Heart Centre, and Hypertension Specialist at Barts Health NHS Trust
Session Time:	Friday, October 9, 9:00-10:30 am ET
Session Title:	Poster Session 2: Clinical Trials in Hypertension and Related Morbidities
Poster Board:	FR461

Title:	Lorundrostat Mitigates Cardiorenal Injury Independent of Blood Pressure Reduction in an L-NAME/Angiotensin II Rat Model
Presenter:	Jose Romero, PhD, Assistant Professor of Medicine at Harvard Medical School, and Associate Physiologist Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, Brigham and Women’s Hospital
Session Time:	Friday, October 9, 9:00-10:30 am ET
Session Title:	Poster Session 2: Aldosterone, Receptors and Signal Transduction
Poster Board:	FR401

Title:	Real-World Utilization and Treatment Patterns of Spironolactone in Patients with Hypertension
Presenter:	Kay Sadik, PharmD, PhD, Director, Health Economics & Outcomes Research/Real-World Evidence (HEOR/RWE), Mineralys Therapeutics
Session Time:	Friday, October 9, 9:00-10:30 am ET
Session Title:	Poster Session 2: Resistant Hypertension
Poster Board:	FR568

Title:	Adherence to Mineralocorticoid Receptor Antagonists for Uncontrolled and Treatment-Resistant Hypertension: A Targeted Literature Review and Meta-Analysis
Presenter:	Kay Sadik, PharmD, PhD, Director, Health Economics & Outcomes Research/Real-World Evidence (HEOR/RWE), Mineralys Therapeutics
Session Time:	Friday, October 9, 9:00-10:30 am ET
Session Title:	Poster Session 2: BP Control and Adherence to Treatment
Poster Board:	FR447

About Launch-HTN 
The Launch-HTN trial (NCT06153693) was a global, randomized, double-blind, placebo-controlled Phase 3 clinical trial of adults whose blood pressure remained uncontrolled despite being on two to five antihypertensive medications. Participants were assigned to one of three groups: lorundrostat 50 mg once daily; lorundrostat 50 mg once daily with the option to increase to 100 mg at week six based on prespecified criteria; or placebo. The primary endpoint was change from baseline in systolic blood pressure at six weeks versus placebo, measured by automated office blood pressure monitoring.

About Explore-OSA

The Explore-OSA trial (NCT06785454) was a randomized, double-blind, placebo-controlled, crossover Phase 2 clinical trial. This proof-of-concept trial was designed to evaluate the efficacy, safety and tolerability of lorundrostat in overweight or obese adults with moderate-to-severe OSA and hypertension. Participants in Explore-OSA received lorundrostat 50 mg once daily and placebo in sequential treatment periods, with continuous monitoring of blood pressure during overnight polysomnography. The primary efficacy endpoint of the trial was absolute change from baseline in apnea-hypopnea index after four weeks of active treatment compared to placebo. The first secondary endpoint was automated office blood pressure, and additional endpoints were nighttime blood pressure and sleep and cardiovascular health measures.

About Hypertension

Having sustained, elevated blood pressure (or hypertension) increases the risk of heart disease, heart attack and stroke, which are leading causes of death in the United States. In 2022, more than 685,000 deaths in the United States included hypertension as a primary or contributing cause. Hypertension and related health issues resulted in an estimated annual economic burden of about $219 billion in the United States in 2019.

Less than 50% of hypertensive patients achieve their blood pressure goal with currently available medications. Dysregulated aldosterone levels are a key factor in driving hypertension in approximately 30% of all hypertensive patients.

About Lorundrostat

Lorundrostat is an investigational, proprietary, orally administered, highly selective aldosterone synthase inhibitor being developed for the treatment of uncontrolled hypertension (uHTN) or resistant hypertension (rHTN), as well as related comorbidities, such as chronic kidney disease, obstructive sleep apnea and other diseases driven by dysregulated aldosterone. Lorundrostat was designed to reduce aldosterone levels by inhibiting CYP11B2, the enzyme responsible for its production. Lorundrostat has 374-fold selectivity for aldosterone-synthase inhibition versus cortisol-synthase inhibition in vitro, has an observed half-life of 10-12 hours and demonstrated a 40-70% reduction in plasma aldosterone concentration in participants with hypertension.

Mineralys has completed six late-stage clinical trials of lorundrostat supporting its efficacy and safety profile while also validating aldosterone as an integral therapeutic target in uHTN and rHTN. The clinical program includes two pivotal, registrational trials, the Phase 3 Launch-HTN trial and Phase 2 Advance-HTN trial, which support the robust, durable and clinically meaningful reductions in systolic blood pressure by lorundrostat. Lorundrostat was well tolerated in both trials with a favorable safety profile.

About Mineralys

Mineralys Therapeutics is a biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as chronic kidney disease, obstructive sleep apnea and other diseases driven by dysregulated aldosterone. Its initial product candidate, lorundrostat, is an investigational, proprietary, orally administered, highly selective aldosterone synthase inhibitor. Mineralys is based in Radnor, Pennsylvania, and was founded by Catalys Pacific. For more information, please visit https://mineralystx.com. Follow Mineralys on LinkedIn, X and Bluesky.

Forward-Looking Statements

Mineralys Therapeutics cautions you that statements contained in this press release regarding matters that are not historical facts are forward-looking statements. The forward-looking statements are based on Mineralys’ current beliefs and expectations and include, but are not limited to, statements regarding the potential therapeutic benefits of lorundrostat. Actual results may differ from those set forth in this press release due to the risks and uncertainties inherent in Mineralys’ business, including, without limitation: any delays in the Food and Drug Administration’s (FDA) review of Mineralys’ accepted new drug application (NDA), including as a result of a government shutdown or reductions in agency funding or personnel; the results of Mineralys’ clinical trials, including the Launch-HTN and Advance-HTN trials, may not be deemed sufficient by the FDA to serve as the basis for regulatory approval of lorundrostat; later developments with the FDA may be inconsistent with the feedback from prior meetings, including whether the proposed pivotal program will support registration of lorundrostat following the FDA’s review of Mineralys’ NDA submission; the risk that future funding under the secured debt facility may not be available on the timeframe Mineralys expects, or at all, including as a result of its failure to meet the conditions required for such funding or failure to comply with the affirmative and negative covenants under the debt facility; Mineralys may not be able to reach agreement on the proposed termination of its license agreement with Tanabe on its expected timeframe, or at all; Mineralys’ future performance is dependent entirely on the success of lorundrostat; potential delays in the commencement, enrollment and completion of clinical trials and nonclinical studies; Mineralys’ dependence on third parties in connection with manufacturing, research and clinical and nonclinical testing; unexpected adverse side effects or inadequate efficacy of lorundrostat that may limit its development, regulatory approval and/or commercialization; unfavorable results from clinical trials and nonclinical studies; results of prior clinical trials and studies of lorundrostat are not necessarily predictive of future results; macroeconomic trends and uncertainty with regard to high interest rates, elevated inflation, tariffs and other trade policies, and the potential for a local and/or global economic recession; Mineralys’ ability to maintain undisrupted business operations due to any pandemic or future public health concerns; regulatory developments in the United States and foreign countries; Mineralys’ reliance on its exclusive license with Tanabe to provide Mineralys with intellectual property rights to develop and commercialize lorundrostat; and other risks described in Mineralys’ filings with the Securities and Exchange Commission (SEC), including under the heading “Risk Factors” in its annual report on Form 10-K, and any subsequent filings with the SEC. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and Mineralys undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.

Contact:

Investor Relations
investorrelations@mineralystx.com

Media Relations
Melyssa Weible
Elixir Health Public Relations
Email: mweible@elixirhealthpr.com

WALTHAM, Mass., Oct. 01, 2026 (GLOBE NEWSWIRE) — Akebia Therapeutics^®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted one newly-hired employee options to purchase an aggregate of 8,400 shares of Akebia’s common stock on September 30, 2026. The options were granted as an inducement material to the employee entering into employment with Akebia. The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4).

The options have an exercise price of $0.92 per share, which is equal to the closing price of Akebia’s common stock on the grant date. The stock options vest over four years, with 25% of the shares vesting on the first anniversary of the grant date and the remaining 75% of shares vesting quarterly thereafter, in each case, subject to the new employee’s continued service with Akebia. Each stock option has a 10-year term and is subject to the terms and conditions of Akebia’s inducement award program and a stock option agreement covering the grant.

About Akebia Therapeutics

Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease. Akebia was founded in 2007 and is headquartered in Waltham, Massachusetts. For more information, please visit our website at www.akebia.com, which does not form a part of this release.

Akebia Therapeutics Contact

Mercedes Carrasco
mcarrasco@akebia.com

Nutriband CEO Gareth Sheridan Congratulates Shareholders on Five-Year Nasdaq Listing Anniversary

CEO letter reflects on five years of milestones since the Company’s October 1, 2021 uplisting, as AVERSA™ Fentanyl advances toward an IND filing and the 2021 offering warrants expire as scheduled

ORLANDO, Fla., Oct. 01, 2026 (GLOBE NEWSWIRE) — Nutriband Inc. (NASDAQ: NTRB) today announced that CEO Gareth Sheridan has published a letter to shareholders marking the fifth anniversary of the Company’s listing on the Nasdaq Capital Market, which took effect on October 1, 2021. The letter reviews the key milestones achieved between October 1, 2021 and today and outlines the Company’s priorities for the period ahead. The full text of the letter is below.

Dear Shareholders,

Five years ago today, on October 1, 2021, Nutriband’s common stock and warrants began trading on the Nasdaq Capital Market under the symbols NTRB and NTRBW and on behalf of the entire Nutriband team I want to congratulate and thank every one of you who has been part of that journey.

I always make a point of thanking the many of you who have been with us from the very beginning, and the many more who have joined our common goal along the way. That goal has not changed in five years: to change the world for the better by improving the safety standard of easily abused transdermal drugs, while making sure these safer treatments remain available to the patients who genuinely need them.

When we uplisted, I said that becoming a Nasdaq-listed company would broaden awareness of Nutriband and give us the access to resources and the credibility to move our lead product, AVERSA™ Fentanyl, forward. Looking back over the past five years, I believe we have done exactly that. AVERSA™ Fentanyl has moved from a feasibility concept to a commercially scaled-up product with a global commercial brand name decided, all while we kept a disciplined focus on protecting shareholders from unnecessary dilution.

Five Years of Milestones

Here are some of the key highlights from our first five years as a Nasdaq-listed company.

2021 – 2022: Uplisting and Setting AVERSA™ Fentanyl in Motion

• October 2021: Uplisted to the Nasdaq Capital Market, alongside an underwritten public offering of $6.6 million; together with the concurrent offering, total gross proceeds were approximately $8.7 million.
• January 2022: Signed a feasibility agreement with Kindeva Drug Delivery, a world leader in transdermal manufacturing, to develop AVERSA™ Fentanyl based on our AVERSA™ technology and Kindeva’s FDA-approved transdermal fentanyl patch.
• Expanded the AVERSA™ pipeline to include AVERSA™ Buprenorphine and AVERSA™ Methylphenidate, underlining that AVERSA™ is a platform technology.
• A Health Advances market analysis estimated AVERSA™ Fentanyl could reach peak annual U.S. sales of $80 million to $200 million.¹
• Reported record fiscal-year revenue of $1.4 million, up 56%, and grew AVERSA™ patent coverage to 44 countries.

2023: Recognition, New IP and Revenue Growth

• The USPTO issued new intellectual property for our AVERSA™ technology.
• Showcased AVERSA™ in London and received multiple award nominations at the 2023 pharma industry awards.
• Delivered strong revenue growth from our Pocono Pharma subsidiary, helping to reduce our burn rate through clinical development.
• Launched our own Active Intelligence (AI Tape) brand, manufactured in Cherryville, North Carolina, with former NFL quarterback Donovan McNabb as brand ambassador.
• Strengthened our balance sheet by converting $2 million of debt into equity with a large strategic shareholder.

2024: From Feasibility to Commercial Development

• Signed a Commercial Development and Clinical Supply Agreement with Kindeva, replacing the feasibility agreement and marking our transition from feasibility toward potential commercialization.
• Secured patents in China and Hong Kong, extending AVERSA™ patent protection to 46 countries, and received a U.S. Notice of Allowance for the AVERSA™ trademark.
• Reported record Q3 revenue of $645,796, up 51% year over year, with Pocono-manufactured products available at Target, Walmart, Walgreens and CVS.
• Entered an exclusive supplier agreement with Fit For Life Group, a brand licensee for Adidas, Reebok and New Balance, and launched our Mosquito Repellent Patch in Costa Rica.

2025: Scale-Up, FDA Engagement and Shareholder Rewards

• February: Received a Notice of Allowance for a new U.S. patent covering AVERSA™, and signed an addendum with Kindeva formalizing our exclusive partnership on a shared development cost basis in exchange for milestone payments.
• June: The USPTO issued U.S. Patent No. 12,318,492, “Abuse and Misuse Deterrent Transdermal Systems,” adding significant time to our patent protection. We also completed the commercial manufacturing process scale-up for AVERSA™ Fentanyl.
• July: Issued a 25% Preferred Stock dividend to all shareholders, with each preferred share convertible into one common share following FDA approval of AVERSA™ Fentanyl. We were also added to four indexes: the Russell Microcap, Russell Microcap Growth, Russell 3000E and Russell 3000E Growth.
• August: Were granted a Type C meeting with the U.S. FDA to receive feedback on our Chemistry, Manufacturing and Controls plans from IND submission through a 505(b)(2) NDA approval and commercialization.

2026: Building Toward the Clinic

• January: Held our Annual Shareholders Meeting in Orlando and welcomed two new directors, Alessandro Puddu and Viorica Carlig, to our Board.
• August: Presented as part of the CEO Spotlight at the 2026 Georgia Life Sciences Summit.
• September: Received a Notice of Publication from the USPTO for the commercial brand name trademarks for our abuse-deterrent fentanyl patch, a key step toward submitting our worldwide brand name to the FDA and other regulators.
• September: Attended the inaugural Nasdaq Life Sciences Advisory Board (LaB) Biotech Summit, appointed decorated Navy SEAL and veterans’ health advocate Robert J. O’Neill to our Advisory Board, and was featured in a new Nick Shirley documentary on America’s opioid crisis.
• September 30: 5 Year tradeable warrants under the symbol NTRBW from Nasdaq uplisting expired.

Shareholder Value and the Road Ahead

Shareholder value has always been, and remains, a core focus for us. Over five years we have been deliberately reluctant to raise capital in the open market in ways that could introduce additional warrants or unfavorable capital structures, choosing instead non-dilutive and strategic routes wherever possible.

This anniversary also closes an important chapter. The warrants issued in our 2021 uplisting expired as scheduled on September 30, 2026, with no extension and no repricing, and have been removed from the NTRBW Nasdaq listing. Internally, we believe these warrants were a major contributor to the volatility in our stock in recent years, and we enter our sixth year on Nasdaq with a cleaner capital structure and no debt.

Looking ahead, our focus is firmly on advancing AVERSA™ Fentanyl toward an NDA filing. Our priorities include filing a nonprovisional patent application that could extend protection of AVERSA™-based products to 2046, manufacturing clinical supplies for our Human Abuse Liability study, filing an Investigational New Drug application with the FDA, and initiating clinical studies. AVERSA™ Fentanyl has the potential to become the world’s first abuse-deterrent opioid transdermal patch.

If you haven’t already, please sign up for our email alerts at www.Nutriband.com to receive the latest news and announcements as they become available.

Your continued support and belief in our vision have been pivotal to reaching these milestones. Five years on, our commitment to shareholder value as our number one focus is unchanged, and as we move closer to commercialization of AVERSA™ Fentanyl, I have no doubt that strategy will continue to shine through. Thank you for your trust, confidence and investment in Nutriband Inc.

Sincerely,

Gareth Sheridan CEO, Nutriband Inc.

¹ Health Advances AVERSA Fentanyl market analysis report, 2022

About Nutriband Inc.

We are primarily engaged in the development of a portfolio of transdermal pharmaceutical products. Our lead product under development is an abuse-deterrent fentanyl patch incorporating our AVERSA™ abuse-deterrent technology. AVERSA™ technology can be incorporated into any transdermal patch to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential.

The Company’s website is www.nutriband.com. Any material contained in or derived from the Company’s websites or any other website is not part of this press release.

Forward-Looking Statements

Certain statements contained in this press release, including, without limitation, statements containing the words “believes,” “anticipates,” “expects” and words of similar import, constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve both known and unknown risks and uncertainties. The Company’s actual results may differ materially from those anticipated in its forward-looking statements as a result of a number of factors, including the Company’s ability to develop its proposed abuse-deterrent fentanyl transdermal system and other proposed products, its ability to obtain patent protection for its abuse-deterrent technology, its ability to obtain the necessary financing to develop products and conduct the necessary clinical testing, its ability to obtain U.S. Food and Drug Administration approval to market any product it may develop in the United States and to obtain any other regulatory approval necessary to market any product in other countries, its ability to market any product it may develop, its ability to create, sustain, manage or forecast its growth; its ability to attract and retain key personnel; changes in the Company’s business strategy or development plans; competition; business disruptions; adverse publicity and international, national and local general economic and market conditions and risks generally associated with an undercapitalized developing company, as well as the risks contained under “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in the Company’s periodic and current reports on Forms 10-K, 10-Q and 8-K and the Company’s other filings with the Securities and Exchange Commission. Except as required by applicable law, we undertake no obligation to revise or update any forward-looking statements to reflect any event or circumstance that may arise after the date hereof.

Nutriband is a registered trademark of Nutriband, Inc. AVERSA is a trademark of Nutriband, Inc.

Contact Information:

Nutriband Inc.

Phone: 407-377-6695

Email: info@nutriband.com

SOURCE: Nutriband Inc.

WARSAW, N.Y., Oct. 01, 2026 (GLOBE NEWSWIRE) — Financial Institutions, Inc. (NASDAQ: FISI) (the “Company”), the parent company of Five Star Bank and Courier Capital, LLC, will release results for the third quarter ending September 30, 2026, after the market closes on October 29, 2026.

Management will host an earnings conference call and audio webcast on October 30, 2026 at 8:30 a.m. Eastern Time. The call will be hosted by Martin K. Birmingham, President and Chief Executive Officer, and W. Jack Plants II, Chief Financial Officer and Treasurer. Within the United States, participants may access the call by dialing 1-877-425-9470 and requesting the “Financial Institutions, Inc. Third Quarter 2026 Earnings Conference Call.” A live webcast will also be available at https://viavid.webcasts.com/starthere.jsp?ei=1776786&tp_key=90ac35b0c7 in listen-only mode. A replay of the webcast will be available on the Company’s IR website, www.FISI-Investors.com, for at least 30 days.

About Financial Institutions, Inc.
Financial Institutions, Inc. (NASDAQ: FISI) is a financial holding company with approximately $6.3 billion in assets as of June 30, 2026, offering banking and wealth management products and services. Its Five Star Bank subsidiary provides consumer and commercial banking and lending services to individuals, municipalities and businesses through banking locations spanning Western and Central New York and a commercial loan production office serving the Mid-Atlantic region. Courier Capital, LLC offers customized investment management, financial planning and consulting services to individuals and families, businesses, institutions, non-profits and retirement plans. Learn more at Five-StarBank.com and FISI-Investors.com.

CONTACT: For additional information contact:
Kate Croft
Director of Investor Relations and Corporate Communications
(716) 817-5159
FISI-Investors@five-starbank.com